James H Ludens

US Patent:

56957564, Dec 9, 1997

Filed:

Jun 6, 1995

Appl. No.:

8/466795

Inventors:

Mordecai P. Blaustein - Baltimore MD
John M. Hamlyn - Baltimore MD
Douglas W. Harris - Portage MI
James H. Ludens - Portage MI
William Rodney Mathews - Plainwell MI
Jed F. Fisher - Three Rivers MI
Frederic Mandel - Vicksburg MI
Donald W. DuCharme - Paw Paw MI

Assignee:

University of Maryland at Baltimore - Baltimore MD

International Classification:

A61K 39385
A61K 39395
C07K 1626
C07K 1702

US Classification:

4241301

Abstract:

Methods for diagnosing pre-hypertension, hypertension, congestive cardiomyopathy, renal failure, salt-sensitivity and adenomas and endocrine cell hyperplasias are disclosed. Also disclosed are methods for monitoring hypertension therapy, congestive cardiomyopathy therapy, renal failure therapy and adenoma and endocrine cell hyperplasia therapy. These methods involve using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject. Additionally, methods for treating a hypertensive subject by inducing passive or active immunity to human ouabain in the subject are disclosed, along with an antibody having binding specificity for ouabain.

US Patent:

51642964, Nov 17, 1992

Filed:

Aug 31, 1990

Appl. No.:

7/575714

Inventors:

Mordecai P. Blaustein - Baltimore MD
John M. Hamlyn - Baltimore MD
Douglas W. Harris - Portage MI
James H. Ludens - Portage MI
William R. Mathews - Plainwell MI
Jed F. Fisher - Three Rivers MI
Frederic Mandel - Vicksburg MI
Donald W. DuCharme - Paw Paw MI

Assignee:

University of Maryland at Baltimore - Baltimore MD

International Classification:

C12Q 100
G01N 3353

US Classification:

435 724

Abstract:

Methods for diagnosing pre-hypertension, hypertension, congestive cardiomyopathy, renal failure, salt-sensitivity and adenomas and endocrine cell hyperplasias are disclosed. Also disclosed are methods for monitoring hypertension therapy, congestive cardiomyopathy therapy, renal failure therapy and adenoma and endocrine call hyperplasia therapy. These methods involve using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject. Additionally, methods for treating a hypertensive subject by inducing passive or active immunity to human ouabain in the subject are disclosed, along with an antibody having binding specificity for ouabain.

US Patent:

44630131, Jul 31, 1984

Filed:

Aug 18, 1982

Appl. No.:

6/409225

Inventors:

Robert J. Collins - Kalamazoo MI
Lester J. Kaplan - Kalamazoo MI
James H. Ludens - Portage MI
Philip F. Von Voigtlander - Gunplain Township, Allegan County MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

A61K 3140

US Classification:

424274

Abstract:

Conditions of inappropriate hyperhydration in warm blooded animals can be treated with an essentially water only diuretic drug compound selected from the group ##STR1## wherein m, n, p, A, E, R, R. sub. 1, R. sub. 2, X, Y and Z are as defined in the specification, e. g. , trans-3,4-dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1,4-dioxaspiro[4. 5]dec-8 -yl]benzeneacetamide, or a pharmaceutically acceptable salt thereof, ##STR2## wherein R, R. sub. 1, R. sub. 2, R. sub. 3, P, Q, X and Y are as defined in the specification, e. g. , 3,4-dichloro-N-[[8-(1-pyrrolidinyl)-1,4-dioxaspiro[4. 5]-dec-8-yl]methyl]be nzeneacetamide, or a pharmaceutically acceptable salt thereof, or ##STR3## where R, R. sup. 1, R. sup. 2, X and Y are as defined in the specification, e. g. , trans-(1)-2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] acetamide, or ##STR4## wherein p, n, q, X, Y, R, R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, E, R. sub. 5, R. sub.

US Patent:

45144079, Apr 30, 1985

Filed:

Mar 17, 1983

Appl. No.:

6/476181

Inventors:

Jackson B. Hester - Comstock Township, Kalamazoo County MI
James H. Ludens - Portage MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

A61K 3155
C07D48704

US Classification:

514220

Abstract:

Triazolo-benzodiazepine-1-ethanamines of the formulas ##STR1## where R, R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4 and Ring A are as defined in the specification, e. g. , 8-chloro-N,N-dimethyl-. beta. ,6-diphenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benz odiazepine-1-ethanamine, and pharmacologically acceptable salts thereof, have been found to have substantial diuretic, natriuretic, but little, if any, kaliuretic activity, which can be used alone, or concomittently with other diuretic drugs such as furosemide or hydrochlorothiazide and/or with antihypertensive agents such as propranolo, captopril, minoxidil, prazosin, guanadrel sulfate, whose actions are supplemented by the action of a diuretic drug.

US Patent:

56681577, Sep 16, 1997

Filed:

Jun 25, 1996

Appl. No.:

8/666502

Inventors:

Stephen J. Humphrey - Kalamazoo MI
Kaushik D. Meisheri - Kalamazoo MI
James H. Ludens - Kalamazoo MI
Jackson B. Hester - Galesburg MI

Assignee:

Pharmacia & Upjohn Company - Kalamzoo MI

International Classification:

A61K 3144
C07D21375

US Classification:

514353

Abstract:

Cyanoguanidine compounds of formula (I) and its pharmaceutically acceptable acid addition salts wherein R. sub. 1 is hydrogen or methyl; R. sub. 2 is C. sub. 1 -C. sub. 6 alkyl, C. sub. 2 -C. sub. 6 alkenyl, C. sub. 2 -C. sub. 6 alkynyl, C. sub. 3 -C. sub. 5 cycloalkyl, C. sub. 3 -C. sub. 5 cycloalkenyl hydroxy methyl, methoxy-C. sub. 1 -C. sub. 5 alkyl, or R. sub. 1 and R. sub. 2 are combined to form a C. sub. 3 -C. sub. 6 carbocyclic ring; R. sub. 3 and R. sub. 4 are each independently selected to be hydrogen, C. sub. 1 -C. sub. 4 alkyl, F, Cl, Br, I or CF. sub. 3 ; R. sub. 5 is hydrogen, F or Cl; R. sub. 6 is hydrogen, --NH. sub. 2, --NHCH. sub. 3, --NHC. sub. 2 H. sub. 5, --NHCH(CH. sub. 3). sub. 2, --N(CH. sub. 3). sub. 2, --N(C. sub. 2 H. sub. 5). sub. 2, NH(CH. sub. 2). sub. m, --OC. sub. 1 -C. sub. 3 alkyl (where m is 2 or 3), --NHC(O)C. sub. 1 -C. sub.

US Patent:

54299284, Jul 4, 1995

Filed:

Jul 28, 1992

Appl. No.:

7/921207

Inventors:

Mordecai P. Blaustein - Baltimore MD
John M. Hamlyn - Baltimore MD
Douglas W. Harris - Portage MI
James H. Ludens - Portage MI
William R. Mathews - Plainwell MI
Jed F. Fisher - Three Rivers MI
Frederic Mandel - Vicksburg MI
Donald W. DuCharme - Paw Paw MI

Assignee:

University of Maryland at Baltimore - Baltimore MD

International Classification:

G01N 3353
G01N 33555
G01N 33567

US Classification:

435 724

Abstract:

Methods using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject are disclosed.

US Patent:

56333749, May 27, 1997

Filed:

Nov 20, 1995

Appl. No.:

8/553308

Inventors:

Stephen J. Humphrey - Kalamazoo MI
Kaushik D. Meisheri - Kalamazoo MI
James H. Ludens - Kalamazoo MI
Jackson B. Hester - Galesburg MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

C07D23942
C07D23948

US Classification:

544322

Abstract:

Pyrimidine-cyanoguanidine compounds of Formula I and its pharmaceutically acceptable acid addition salts ##STR1## wherein R. sub. 1 is hydrogen or methyl; R. sub. 2 is C. sub. 1 -C. sub. 6 alkyl, C. sub. 2 -C. sub. 6 alkenyl, C. sub. 2 -C. sub. 6 alkynyl, C. sub. 3 -C. sub. 5 cycloalkyl, C. sub. 3 -C. sub. 5, hydroxy methyl, cycloalkyl methoxy-C. sub. 1 -C. sub. 5 alkyl, or R. sub. 1 and R. sub. 2 are combined to form a C. sub. 3 -C. sub. 6 carbocyclic ring; R. sub. 3 and R. sub. 4 are each independently selected to be hydrogen, C. sub. 1 -C. sub. 4 alkyl, F, Cl, Br, I or CF. sub. 3 ; R. sub. 5 is hydrogen, F or Cl; R. sub. 6 is hydrogen, --NH. sub. 2, --NHCH. sub. 3, --NHC. sub. 2 H. sub. 5, --NHCH(CH. sub. 3). sub. 2, --N(CH. sub. 3). sub. 2, --N(C. sub. 2 H. sub. 5). sub. 2, NH(CH. sub. 2). sub. m --OC. sub. 1 --C. sub. 3 alkyl (where m is 2 or 3), --NHC(O)C. sub. 1 -C. sub.

US Patent:

55677223, Oct 22, 1996

Filed:

Feb 6, 1995

Appl. No.:

8/384562

Inventors:

Stephen J. Humphrey - Kalamazoo MI
Kaushik D. Meisheri - Kalamazoo MI
James H. Ludens - Kalamazoo MI
Jackson B. Hester - Galesburg MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

C07D21375
A61K 3144

US Classification:

514353

Abstract:

Cyanoguanidine compounds of Formula I and its pharmaceutically acceptable acid addition salts ##STR1## wherein R. sub. 1 is hydrogen or methyl; R. sub. 2 is C. sub. 1 -C. sub. 6 alkyl, C. sub. 2 -C. sub. 6 alkenyl, C. sub. 2 -C. sub. 6 alkynyl, C. sub. 3 -C. sub. 5 cycloalkyl, C. sub. 3 -C. sub. 5 cycloalkenyl hydroxy methyl, methoxy-C. sub. 1 -C. sub. 5 alkyl, or R. sub. 1 and R. sub. 2 are combined to form a C. sub. 3 -C. sub. 6 carbocyclic ring; R. sub. 3 and R. sub. 4 are each independently selected to be hydrogen, C. sub. 1 -C. sub. 4 alkyl, F, Cl, Br, I or CF. sub. 3 ; R. sub. 5 is hydrogen, F or Cl; R. sub. 6 is hydrogen, --NH. sub. 2, --NHCH. sub. 3, --NHC. sub. 2 H. sub. 5, --NHCH(CH. sub. 3). sub. 2, --N(CH. sub. 3). sub. 2, --N(C. sub. 2 H. sub. 5). sub. 2, NH(CH. sub. 2). sub. m -- OC. sub. 1 -C. sub. 3 alkyl (where m is 2 or 3), --NHC(O)C. sub. 1 -C. sub.